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1. INTRODUCTION 
     
       Heparin-binding protein 17 (HBp17) was originally purified from the medium conditioned 
by human epidermoid carcinoma cell line A431, and later renamed as fibroblast growth 
factor-binding protein-1 (FGFBP-1). HBp17/FGFBP-1 was initially found to bind FGF-1 and 
FGF-2 in a non-covalent and reversible manner. Recently, it was reported that up-regulation of 
HBp17/FGFBP-1 was found in various tumors, including head and neck, skin and colon cancers. 
Binding of HBp17/FGFBP-1 to FGF-2 mediates the release of immobilized FGF-2 from the 
extracellular matrix allowing it to bind its receptor, suggesting that HBp17/FGFBP-1 serves as an 
extracellular pivotal switching molecule for FGF-2.  
  FGF-2 is the prototypic member of a family containing at least 23 structurally-related 
polypeptide growth factors. It is expressed ubiquitously in a variety of tumor cells including oral 
squamous cell carcinomas (OSCC). In vitro, FGF-2 is a potent mitogen for different cell types, 
including vascular endothelial cells, fibroblasts and cancer cells such as OSCC cells. In vivo, FGF-2 
is a potent inducer of angiogenesis and has pleiotropic effects both on development, differentiation 
in various organs, and tumorigenesis.  
        1α,25-dihydroxyvitamin D3 (VD3) is a multifunctional hormone that exerts its action 
through the vitamin D receptor (VDR). The anti-cancer potential of vitamin D analogs on its ability 
to inhibit growth of cancer cells, induce apoptosis and even inhibit angiogenesis has been reported. 
One of the mechanisms of VD3 is by inhibiting NF-кB activation and signaling. Based on the 
promoter sequence in the HBp17/FGFBP-1, it has been speculated that the sequence has a possible 
NF-кB binding site. Thus, we tested the hypothesis that HBp17/FGFBP-1 expression was regulated 
by NF-кB by manipulating this particular binding site, and then studied the possibility to inhibit the 
activation of FGF-2 in OSCC cells by repressing the expression of HBp17/FGFBP-1 using VD3.
  
2. MATERIALS AND METHODS 
 
   Oral cancer cell lines; UE: HO-1-u-1 and NA (oral squamous carcinoma cell lines), A431 
(dermoid carcinoma cell lines) have been used in this study. The cells were treated periodically with 
VD3 (40nM) in serum-free defined medium designated RD6F. The mRNA and protein expression 
for HBp17/FGFBP-1, FGF-2, Vitamin D3 receptor (VDR) and NF-κB molecules (IκBα, p65 and 
p50) were quantified using quantitative real-time PCR (qRT-PCR) and western blotting (WB). 
Immunofluorescence analysis was performed to reveal the effect of VD3 on the distribution of 
HBp17/FGFBP-1 in UE cells. Meanwhile, a luciferase reporter assay was performed to determine 
HBp17/FGFBP-1 promoter activity (region between -217 and +61; region containing deduced 
NFκB binding site) in response to the treatment.  
   Additionally, effect of VD3 on the expression of HBp17/FGFBP-1 and FGF-2 was examined 
using quantitative enzyme-linked immunosorbent assay (ELISA). VDR RNAi-transfected UE cells 
(siVDR) were used to determine the role of VDR on HBp17/FGFBP-1 expression by the VD3.  
 
3. RESULTS 
 
        HBp17/FGFBP-1 mRNA and protein level were significantly down-regulated by VD3 
(40nM), with highest inhibition observed at 12 hour after the treatment. The expression levels of 
FGF-2, VDR, p65 and p50 did not change after the treatment. Suppression on HBp17/FGFBP-1 
expression was also confirmed by immunofluorescence analysis. As a result of a luciferase reporter 
assay, promoter activity of HBp17/FGFBP-1 was significantly suppressed by the VD3 treatment. 
On another note, the level of IκBα, which is known as an NFκB regulator was up-regulated.  
In siVDR cells, HBp17/FGFBP-1 expression was modestly suppressed (20%) by VD3 
treatment compared to that of wild type where HBp17/FGFBP-1 expression was inhibited in higher 
degree (70%). By contrast, IκBα expression was unaffected in siVDR cells, while its expression 
was strongly induced (70%) in wild-type cells. 
Although VD3 did not show to have direct effect on FGF-2 expression, it has been 
revealed by ELISA that the level in the medium conditioned by the cells treated with VD3 
significantly decreased.   
 
4. DISCUSSION 
 
  The data from quantitative RT-PCR, western blotting, and ELISA clearly showed that 
down-regulation of HBp17/FGFBP-1 resulted in inhibition of the FGF-2 release from the 
extracellular matrix.  
      Apart from HBp17/FGFBP-1 down-regulation, analysis of VD3-treated cells revealed an 
up-regulation of IκBα which function as the regulator of NFκB activity. Such an observation in 
previous report has been an indicator for an inhibition of NF-κB activity. The result by the 
Luciferase reporter assay demonstrated that the speculated NF-κB binding site in region between 
-217 and +61 of HBp17/FGFBP-1 promoter sequence is a functional NF-κB binding site.  
In siVDR cells, inhibitory effect of VD3 on the expression of HBp17/FGFBP-1 was diminished 
compared to that on siControl cells, suggesting these VD3 inhibition on HBp17/FGFBP-1 is 
mediated by VDR. These results strongly suggest the possibility that 1α,25(OH)2D3 might be a 
useful agent for the oral cancer therapy by targeting NF-κB and HBp17/FGFBP-1 molecules.   
